| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | MDP1; PEO; PolG alpha; POLG; POLG1; POLGA; SANDO; SCAE |
| Entrez GeneID | 5428 |
| WB Predicted band size | Calculated MW: 140 kDa; Observed MW: 140 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthetic peptide of human POLG |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3条示例性质的参考文献(内容为虚构，仅作格式参考)：
1. **《POLG抗体在自身免疫性神经系统疾病中的诊断意义》**
作者：Smith J, et al.
摘要：研究探讨了POLG抗体在慢性进行性眼外肌麻痹(CPEO)患者血清中的检测价值，发现其与线粒体DNA缺失存在关联，可作为辅助诊断标志物。
2. **《抗POLG抗体与皮肌炎患者临床表现的相关性分析》**
作者：Zhang L, et al.
摘要：通过ELISA检测皮肌炎患者血清，发现POLG抗体阳性率显著高于健康对照组，且与肌无力和皮肤病变严重程度呈正相关。
3. **《线粒体抗体谱中POLG抗体的临床特征研究》**
作者：Garcia R, et al.
摘要：比较了POLG抗体与其他线粒体相关抗体(如抗M2抗体)的临床差异，指出POLG抗体阳性患者更易出现多系统受累及神经退行性变。
(注：以上文献为示例，实际文献请通过PubMed或Google Scholar查询。)
POLG antibodies target DNA polymerase gamma, the enzyme responsible for replicating and repairing mitochondrial DNA (mtDNA). Encoded by the nuclear POLG gene, this 140 kDa protein consists of a polymerase domain and an exonuclease proofreading domain. POLG is critical for maintaining mtDNA integrity, and its dysfunction leads to mitochondrial disorders due to impaired energy production in cells.
POLG mutations are linked to diverse diseases, including progressive external ophthalmoplegia (PEO), Kearns-Sayre syndrome, and Alpers-Huttenlocher syndrome. These conditions often manifest with neurological, muscular, or hepatic symptoms. POLG antibodies are essential tools in research and diagnostics, enabling detection of POLG protein expression, localization, and mutation-related abnormalities via techniques like Western blotting, immunohistochemistry, and ELISA. They help correlate genetic variants with clinical phenotypes, study disease mechanisms (e.g., mtDNA depletion), and evaluate therapeutic interventions. Commercial availability of POLG antibodies has advanced studies on mitochondrial biology and aging-related pathologies. However, challenges remain in standardizing antibody specificity across experimental models. Ongoing research focuses on clarifying POLG's role in mitochondrial dynamics and developing targeted treatments for POLG-related disorders.
×
